PE25.06 PrEP adherence is associated with periods of HIV risk among adolescent girls and young women in South Africa and ZimbabweE-posterProduct acceptability and adherence
PE25.07 End-users' hypothetical acceptability of a biodegradable implant to prevent HIV and unplanned pregnancy: qualitative insights from South Africa and ZimbabweE-posterProduct acceptability and adherence
PE25.08 PrEP use in the HVTN 702 HIV vaccine efficacy trial conducted in South AfricaE-posterProduct acceptability and adherence
PE25.09 Predictors of PrEP discontinuation and refill delays among over 47,000 clients first starting PrEP in Kenya, Lesotho and Tanzania: Implications for programsE-posterProduct acceptability and adherence
PE25.10 'Men will never take a pill every day if they don't have to': assumptions and realities around acceptability of PrEP among heterosexual menE-posterProduct acceptability and adherence
PE25.11 Mapping HIV prevention product preferences among adolescent girls and young women at high risk of HIV: results from a discrete choice experiment in South AfricaE-posterProduct acceptability and adherence
PE26.01 Surge strategies improve HIV testing efficiency and linkage to treatment among female sex workers in Nairobi, KenyaE-posterTherapeutic vaccines, viral reservoirs and eradication/remission
PE26.02 Effect of a novel HIV-1 RNA testing intervention to detect acute and prevalent HIV infection in young adults and reduce HIV transmission in Kenya: A randomized controlled trialE-posterTherapeutic vaccines, viral reservoirs and eradication/remission
PE27.01 Association between Basal Metabolic Index and vaccine-induced HIV-1 adaptive immunityE-posterTherapeutic vaccines, viral reservoirs and eradication/remission
PE27.02 The influence of HIV-1 subtype C LTR genotype on latency potentialE-posterTherapeutic vaccines, viral reservoirs and eradication/remission
seek-warrow-warrow-eseek-e421 - 430 of 444 items